AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Abscission/NoCut checkpoint regulator

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We utilise our cutting-edge, exclusive workflow to develop focused libraries.

 Fig. 1. The sreening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.

Key features that set our library apart include:

  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q96K21

UPID:

ANCHR_HUMAN

Alternative names:

MLL partner containing FYVE domain; Zinc finger FYVE domain-containing protein 19

Alternative UPACC:

Q96K21; B3KVB2; C9JNF4; H3BUF9; Q86WC2; Q8WU96

Background:

The Abscission/NoCut checkpoint regulator, also known as Zinc finger FYVE domain-containing protein 19, plays a pivotal role in cytokinesis. It ensures the proper timing of abscission, preventing premature resolution of intercellular chromosome bridges and DNA damage accumulation. This protein, alongside CHMP4C, maintains VPS4 at the midbody ring until the abscission checkpoint signaling concludes.

Therapeutic significance:

Linked to Cholestasis, progressive familial intrahepatic, 9 (PFIC9), a severe liver disorder, understanding the Abscission/NoCut checkpoint regulator's role could unveil new therapeutic avenues. The PFIC9-associated variant p.M76V suggests a direct impact on protein function, highlighting its potential as a therapeutic target.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.